// App-Quantinova.ai

: Late Breaking Abstract - The miR-34a/Pdgfra interaction can be targeted to correct defective alveolarization in experimental bronchopulmonary dysplasia

Researchers

Presenter

  • Jordi Ruiz Camp

Principal Investigators

  • Jennifer Quantius

  • Ettore Lignelli

  • Philipp Arndt

  • Ivana Mizikova

  • Elpidofors Sakkas

  • Konstantin Mayer

  • Istvan Vadasz

  • William Richardson

  • Katrin Ahlbrecht

  • Susanne Herold

  • Werner Seeger

  • Rory Morty

Medical Centers

  • Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany,

  • Department of Internal Medicine II, Universities Giessen & Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany,

  • Max Planck Institute for Heart and Luns Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany

  • Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm, Sweden

  • Wolfson Institute of Biomedical Research, University College London, London, United Kingdom

Locations

  • Germany

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Infant Respiratory Distress Syndrome

  • PDGFRA rearrangement

Biomarkers

  • Platelet-derived growth factor receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved